Comparison of embolic materials for treating chronic subdural hematoma
Part of Brain & nervous system, Heart & circulation, Injuries & trauma clinical trials.
This study compares different materials used during a procedure to treat a chronic subdural hematoma (a slow blood collection on the brain). Doctors will use middle meningeal artery embolization (a treatment that blocks abnormal blood vessels) to see which embolic agent works better, which may help your condition heal more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a chronic subdural hematoma (a slow, long-standing blood collection on the brain) and are scheduled for a middle meningeal artery embolization (a procedure to block blood flow to reduce the collection).
- You can give your own consent or have someone legally authorized to consent for you.
- You are not pregnant or breastfeeding.
- You have no severe allergy to the materials used in the embolization (like particles, Onyx, n-BCA, or coils).
- You are able to have an angiogram (a special X-ray that looks at blood vessels) and can return for follow-up visits at 30 and 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well a procedure called middle meningeal artery embolization works for people with chronic subdural hematoma (a collection of old blood on the brain's surface). It uses specific materials to block the blood supply to the hematoma, which may help the body reabsorb it without surgery.
This trial compares a newer, less invasive treatment (embolization) with traditional surgery to treat chronic subdural hematoma (a slow bleed on the brain). It aims to see which approach works better and has fewer side effects.
This trial tests a procedure called middle meningeal artery embolization, which aims to stop the bleeding and reduce the fluid buildup from a chronic subdural hematoma. It may be an option for patients who have a hematoma at least 10mm thick and one or more risk factors such as older age, blood thinners, diabetes, or certain scan features.
This trial studies a procedure called middle-meningeal-artery embolization, which blocks the blood supply to a chronic subdural hematoma (a slow-growing blood collection around the brain). It compares outcomes in people with one-sided versus both-sided bleeds, and aims to see if this less invasive treatment can help reduce the need for surgery or improve recovery.
This trial compares two ways to treat a chronic subdural hematoma (a long-lasting bleed between the brain and its covering): blocking a specific artery versus standard surgery to remove the blood. It may help you and your care team choose the safer and more effective option for your situation.
This trial tests whether adding a drug called bevacizumab (given through an artery in the brain) to a standard procedure called middle meningeal artery embolization (MMAE) helps treat chronic subdural hematoma (a collection of blood on the brain's surface) better than the procedure alone. The study is for people scheduled for MMAE who meet specific size and symptom criteria.
Hear when a new Chronic Subdural Hematoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.